Psychedelics as a potential treatment for borderline personality disorder: A narrative review

Psychedelics may have potential for treating borderline personality disorder by targeting core mechanisms such as emotional dysregulation and rigid self-concepts, but current evidence is largely indirect and there are important safety concerns, highlighting the need for carefully controlled clinical trials.

This narrative review was conducted to evaluate the current evidence for the safety and effectiveness of psychedelics, including ketamine, esketamine, and psilocybin, within the BPD population. BPD is fundamentally characterized by affective instability and interpersonal hypersensitivity. Although psychotherapy remains the gold standard for care, access to specialized programs like Dialectical Behavior Therapy (DBT) is often limited by high costs and long waitlists. Consequently, many patients rely on off-label pharmacological options that frequently lack robust efficacy for core BPD symptoms. Historically, BPD patients were excluded from psychedelic research due to concerns regarding potential safety risks, such as increased suicidality or substance misuse.

In this review, the authors found that psychedelics may have potential for treating borderline personality disorder by targeting core mechanisms such as emotional dysregulation and rigid self-concepts, but current evidence is largely indirect and there are important safety concerns, highlighting the need for carefully controlled clinical trials.

The study calls for more high-quality randomized controlled trials that utilize BPD-specific outcome measures.

Abstract

“Borderline personality disorder (BPD) is a serious mental illness with high rates of morbidity and stigma; however, successful remission is frequently limited by a paucity of accessible treatment options. In an era of growing interest in psychedelics as novel psychiatric treatment modalities, patients with BPD are often excluded from research due to perceived safety risks, particularly pertaining to suicide and substance misuse. However, there is evolving evidence that psychedelic treatment may effectively target core BPD symptoms, in addition to those of the mood and anxiety disorders frequently comorbid with BPD.

As such, characterizing the therapeutic potential of psychedelics in BPD represents an important opportunity to enhance patient outcomes. This narrative review aims to broadly analyze the existing literature on experiences with psychedelics in this population. Data were coalesced from multiple electronic databases (Ovid MEDLINE, PsychInfo, and Embase) to characterize the current evidence for psychedelic safety and effectiveness in individuals with BPD.

The 22 studies included in this review encompass a broad range of study designs and outcomes involving ketamine, esketamine, and psilocybin. There is some preliminary evidence that these psychedelics may be implemented as safe and effective treatments to improve core BPD symptoms and socio-occupational functioning. However, further high-quality evidence focusing on BPD-specific outcomes is needed to better elucidate their potential role as a treatment modality.”

Erin Artna et al  Psychedelics as a potential treatment for borderline personality disorder: A narrative review. Psychiatry Research Volume 361, July 2026, 117152 Read Paper

For more psychedelic news and research, visit the psychedelic health professional network homepage.